US 12,331,109 B2
Antigen binding molecule formats
Tong Zhang, New Rochelle, NY (US); Erica Pyles, New City, NY (US); Michael Rosconi, New City, NY (US); Nina Liu, Chappaqua, NY (US); Supriya Patel, Elmsford, NY (US); Eric Smith, New York, NY (US); Andrew Murphy, Croton-on-Hudson, NY (US); Chia-Yang Lin, Scarsdale, NY (US); and Samuel Davis, New York, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Apr. 19, 2024, as Appl. No. 18/640,981.
Application 18/640,981 is a continuation of application No. 18/318,871, filed on May 17, 2023, granted, now 11,965,020.
Application 18/318,871 is a continuation of application No. 17/666,116, filed on Feb. 7, 2022, granted, now 11,708,407, issued on Jul. 25, 2023.
Application 17/666,116 is a continuation of application No. 16/987,487, filed on Aug. 7, 2020, granted, now 12,215,148.
Claims priority of provisional application 63/050,483, filed on Jul. 10, 2020.
Claims priority of provisional application 62/884,496, filed on Aug. 8, 2019.
Prior Publication US 2024/0294627 A1, Sep. 5, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/244 (2013.01) [A61K 39/395 (2013.01); A61K 47/6845 (2017.08); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 16/2809 (2013.01); C07K 16/30 (2013.01); C07K 16/46 (2013.01); A61K 2039/505 (2013.01); C07K 2317/31 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/522 (2013.01); C07K 2317/53 (2013.01); C07K 2317/55 (2013.01); C07K 2317/64 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 23 Claims
 
1. An antigen-binding molecule comprising:
(a) a first polypeptide chain comprising, in an N- to C-terminal orientation:
(i) a first Fc domain;
(ii) a first linker;
(iii) a first VH domain; and
(iv) a first CH1 domain;
(b) a second polypeptide chain comprising, in an N- to C-terminal orientation:
(i) a second Fc domain;
(ii) a second linker;
(iii) a second VH domain; and
(iv) a second CH1 domain;
(c) a third polypeptide chain comprising a universal light chain, wherein the third polypeptide is associated with the first VH domain and the first CH1 domain to form a first Fab; and
(d) a fourth polypeptide chain comprising a universal light chain, wherein the fourth polypeptide is associated with the second VH domain and the second CH1 domain to form a second Fab.